SANFILIPPO, GIOVANNA ROBERTA
SANFILIPPO, GIOVANNA ROBERTA
Universita' degli Studi di MILANO
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry
2022 B. Vincenzi, A. Napolitano, A. Comandone, R. Sanfilippo, S. Celant, P.P. Olimpieri, S. Di Segni, P. Russo, P.G. Casali
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
2021 V. Zuco, S. Pasquali, M. Tortoreto, S. Brich, S. Percio, G.P. Dagrada, C. Colombo, R. Sanfilippo, C. Lauricella, M. Gounder, R. El Bezawy, M. Barisella, A.P. Dei Tos, P.G. Casali, A. Gronchi, S. Stacchiotti, N. Zaffaroni
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin
2021 C. Fabbroni, G. Fuca, F. Ligorio, E. Fumagalli, M. Barisella, P. Collini, C. Morosi, A. Gronchi, A.P.D. Tos, P.G. Casali, R. Sanfilippo
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma
2021 L. Mannarino, I. Craparotta, S. Ballabio, R. Frapolli, M. Meroni, E. Bello, N. Panini, M. Callari, R. Sanfilippo, P.G. Casali, M. Barisella, C. Fabbroni, S. Marchini, M. D'Incalci
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
2020 R. Sanfilippo, C. Fabbroni, G. Fucà, E. Fumagalli, C. Morosi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
2020 G. Fucà, C. Fabbroni, R. Mancari, S. Manglaviti, G. Bogani, E. Fumagalli, R. Bertulli, C. Morosi, P. Collini, F. Raspagliesi, N. Colombo, P.G. Casali, R. Sanfilippo
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma : A Multicenter, International, Retrospective Study
2019 G. Fucà, N. Hindi, I. Ray-Coquard, V. Colia, A.P. Dei Tos, J. Martin-Broto, M. Brahmi, P. Collini, D. Lorusso, F. Raspagliesi, M.A. Pantaleo, B. Vincenzi, E. Fumagalli, A. Gronchi, P.G. Casali, R. Sanfilippo
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
2019 A. Gronchi, N. Hindi, J. Cruz, J.-. Blay, A. Lopez-Pousa, A. Italiano, R. Alvarez, A. Gutierrez, I. Rincon, C. Sangalli, J.L. Perez Aguiar, J. Romero, C. Morosi, M.P. Sunyach, R. Sanfilippo, C. Romagosa, D. Ranchere-Vince, A.P. Dei Tos, P.G. Casali, J. Martin-Broto
Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas)
2019 R. Sanfilippo, R.L. Jones, J. Blay, A. Le Cesne, S. Provenzano, G. Antoniou, O. Mir, G. Fucà, E. Fumagalli, R. Bertulli, S. Stacchiotti, M. Brahmi, F. Grosso, A. Dufresne, N. Hindi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali
Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas
2019 R. Frapolli, E. Bello, M. Ponzo, I. Craparotta, L. Mannarino, S. Ballabio, S. Marchini, L. Carrassa, P. Ubezio, L. Porcu, S. Brich, R. Sanfilippo, P.G. Casali, A. Gronchi, S. Pilotti, M. D'Incalci
Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis
2019 E. Nizri, M. Fiore, C. Colombo, S. Radaelli, D. Callegaro, R. Sanfilippo, C. Sangalli, P. Collini, C. Morosi, S. Stacchiotti, P.G. Casali, A. Gronchi
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma
2017 V. Colia, E. Fumagalli, S. Provenzano, R. Bertulli, S. Stacchiotti, C. Morosi, P. Collini, A. Gronchi, P.G. Casali, R. Sanfilippo
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
2017 V. Colia, M. Fiore, S. Provenzano, E. Fumagalli, R. Bertulli, C. Morosi, A.P. Dei Tos, M. Barisella, A. Gronchi, P.G. Casali, R. Sanfilippo
Mode of action of trabectedin in myxoid liposarcomas
2014 S. Di Giandomenico, R. Frapolli, E. Bello, S. Uboldi, S.A. Licandro, S. Marchini, L. Beltrame, S. Brich, V. Mauro, E. Tamborini, S. Pilotti, P.G. Casali, F. Grosso, R. Sanfilippo, A. Gronchi, R. Mantovani, R. Gatta, C.M. Galmarini, J.M.F. Sousa-Faro, M. D'Incalci
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma
2014 R. Sanfilippo, R. Bertulli, A. Marrari, E. Fumagalli, S. Pilotti, C. Morosi, A. Messina, A.P. Dei Tos, A. Gronchi, P.G. Casali
Identification of a gene expression driven progression pathway in Myxoid liposarcoma
2014 L. De Cecco, T. Negri, S. Brich, V. Mauro, F. Bozzi, G. Dagrada, V. Disciglio, R. Sanfilippo, A. Gronchi, N. Maurizio D'Incalci, P.G. Casali, S. Canevari, M.A. Pierotti, S. Pilotti
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
2013 S. Stacchiotti, G.P. Dagrada, R. Sanfilippo, T. Negri, I. Vittimberga, S. Ferrari, F. Grosso, G. Apice, M. Tricomi, C. Colombo, A. Gronchi, A.P. Dei Tos, S. Pilotti, P.G. Casali
In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas
2013 F. Bozzi, E. Conca, E. Laurini, P. Posocco, A. Lo Sardo, G. Jocollè, R. Sanfilippo, A. Gronchi, F. Perrone, E. Tamborini, G. Pelosi, M.A. Pierotti, R. Maestro, S. Pricl, S. Pilotti
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
2007 F. Grosso, R.L. Jones, G.D. Demetri, I.R. Judson, J. Blay, A. Le Cesne, R. Sanfilippo, P. Casieri, P. Collini, P. Dileo, C. Spreafico, S. Stacchiotti, E. Tamborini, J.C. Tercero, J. Jimeno, M. D'Incalci, A. Gronchi, J.A. Fletcher, S. Pilotti, P.G. Casali